Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Terazosin and Tolterodine on Ureteral Stent Related Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~If a patient does not meet any exclusion criteria and to be undergone double-J stent indwelling.~Exclusion Criteria:~1. Prior history of pelvic surgery~2. Prior history of Transurethral Resection of the either Prostate or Bladder Tumor~3. Benign prostate hyperplasia~4. Recent or recurrent urinary tract infection~5. Chronic medication with beta-blockers or Anti-cholinergic~6. Pregnancy~7. Prostatitis~8. Prostate cancer~9. Bilateral ureteroscopy or ureteral stenting~10. Age \< 18 and \> 55~11. Stone size \> 20 mm~12. Diabetes~13. Bladder Outlet Obstruction

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Terazosin (Type: ACTIVE_COMPARATOR): None
- Tolterodine (Type: ACTIVE_COMPARATOR): None
- Tolterodine + Terazosin (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).